Ophiomics" startup wins Portugal everis Award 2020
The project wins 10,000 euros and mentoring as part of the national award as well as a direct pass to the international final of the everis Awards, where it will compete for an additional 70,000 euros.
The Ophiomics startup is the winner of the 19th edition of the Portugal everis Award 2020 with its HepatoPredict solution, a victory that gives it access to a cash prize of 10,000 euros, mentoring and a direct pass to the international final of the 2020 everis Award to be held at the end of November, which will award an additional prize of 70,000 euros.
The winning solution takes the form of a medical device (IVD - in vitro diagnostics) that makes it possible to evaluate the level of success of a liver transplant in patients with liver cancer. The solution developed by Ophiomics, which integrates genomic biomarkers and a decision algorithm developed from scratch based on machine learning, aims to support the medical community in the indication of patients for transplants and the identification of those who can benefit from alternative therapies. With the 10,000 euros raised as the winner of the everis Portugal Award and the 10,000 euros in which the advisory services provided by i-deals (everis Group) are valued, Ophiomics aims to consolidate the business idea and strengthen the prototype that will lead to the international final.
Ophiomics is a Portuguese technology-based startup created in 2015 by José Leal, Joana Cardoso Vaz and the Germano de Sousa Group, with the aim of developing and providing precision oncology solutions. In 2019, based on the company's internal research, they repositioned Ophiomics with a new business model centred on HepatoPredict, in which Joana Vaz and José Leal bet on a global market.
For José Leal, Ophiomics' CEO, "it is very gratifying to see HepatoPredict's value proposal and the years of effort and work we have put into its development. We believe that the solution will make a difference and contribute to supporting the medical community in decision making, consolidating personalized therapies and especially saving lives". He also adds: "Our goal is for HepatoPredict to be ready to enter the market by the end of 2021 and, in this context, the support obtained with this award will be fundamental in reinforcing the prototype and the business idea that surrounds it".
The final stage of the everis Portugal Award involved 13 projects in the categories of "New business models in the digital economy", "Industrial technologies" and "Biotechnology and health", selected from over 117 applications.
According to António Brandão de Vasconcelos, President of everis in Portugal and everis foundation trustee, "the quality of the solutions presented at the 19th edition of the everis Awards shows us, once again, that we have very good talents, motivated researchers who are committed to undertake with the results of their research. And it also shows that there are more and more entrepreneurs committed to applying and increasing the potential of technology for the development and quality of the health sector, and this can only be seen with great satisfaction and pride, especially in the current context in which we live".
The everis Awards thus reinforce the everis foundation's conviction that innovation and entrepreneurship will have an undoubted impact on how they help societies and the planet overcome the challenges posed by an unprecedented crisis such as the Covid-19 pandemic. The initiative also reflects the Foundation's commitment to promoting innovation and national entrepreneurship through the development of innovative technology-based business solutions.
In its decision, the jury has valued both the technological innovation of Arkangel AI, and its enormous impact on health and care in areas where access to medical care and health prevention is scarce.
The winner, Arkangel AI, will represent Colombia in the international phase of the 2020 everis Awards.
everis Netherlands and the everis foundation announced Goal 3 as the winner of the first edition of the everis Awards Nederland.
IDOVEN has developed a solution based on Artificial Intelligence in the cloud with washable technology with which it will be possible to detect, early on, cardiac arrhythmias and sudden death, an ailment that affects more than 30,000 people a year in Spain.